<DOC>
	<DOCNO>NCT01838590</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , efficacy sofosbuvir ( SOF ) plus ribavirin ( RBV ) Egyptian adult genotype 4 hepatitis C virus ( HCV ) infection .</brief_summary>
	<brief_title>Sofosbuvir Plus Ribavirin Administered Either 12 24 Weeks Treatment-Naive Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus ( HCV ) Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Molecular Mechanisms Pharmacological Action</mesh_term>
	<criteria>Treatment experience na√Øve subject Chronic genotype 4 HCVinfection Not coinfected HIV Screening laboratory value within define threshold Use highly effective contraception method Subject must able comply dose instruction study drug administration able complete study schedule assessment . History clinically significant chronic liver disease Pregnant nursing female male pregnant female partner History clinicallysignificant illness major medical disorder may interfere subject treatment , assessment compliance protocol Excessive alcohol ingestion significant drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Liver Diseases</keyword>
	<keyword>Digestive System Diseases</keyword>
	<keyword>Hepatitis , Viral , Human</keyword>
	<keyword>Virus Diseases</keyword>
	<keyword>Enterovirus Infections</keyword>
	<keyword>Picornaviridae Infections</keyword>
	<keyword>RNA Virus Infections</keyword>
	<keyword>Flaviviridae Infections</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Anti-Infective Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Antimetabolites</keyword>
	<keyword>Molecular Mechanisms Pharmacological Action</keyword>
	<keyword>HCV genotype 4 ( GT-4 )</keyword>
	<keyword>HCV</keyword>
	<keyword>Sustained Virologic Response</keyword>
	<keyword>Direct Acting Antiviral</keyword>
	<keyword>Combination Therapy</keyword>
	<keyword>GS-7977</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Open Label</keyword>
	<keyword>Sofosbuvir</keyword>
	<keyword>Additional relevant MeSH term :</keyword>
	<keyword>Hepatitis</keyword>
	<keyword>Hepatitis , Chronic</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Hepatitis C , Chronic</keyword>
</DOC>